Clinical trial
Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients…
NCT00296387 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00296387 |
|---|---|
| Title | Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome |
| Official title | Comparison of the Effects Noted in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With acUte Coronary Syndrome - CENTAURUS |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acute Coronary Syndrome |
| Intervention type | Drug |
| Interventions | Rosuvastatin, Atorvastatin |
| Enrollment | 1,160 |
| Start date | Jan 1, 2006 |
| Completion | Oct 1, 2007 |
| First posted | Feb 27, 2006 |
| Last update posted | Dec 17, 2007 |
| Countries | Belgium, Canada, Estonia, France, Greece, Hungary, Ireland, Italy, Portugal, Spain, Tunisia |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: